based on 2012 estimates of $6.15 makes this steady performer look like a definite buy. 16 times $6.15 yields a price target of $98 and this stock has traded at a PE of 16 times current year earnings (or higher) at some point each year for the past decade. Relative safety in this medical supplies leader given the global growth in demand for its products, especially in emerging markets. Excellent financial strength as well. Not a ton of upside, but 25-35% upside over the next year ain't bad for this low risk, low beta leader!